Neuroendocrine Tumors, Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors
Conditions
Keywords
177Lu-DOTATATE, Pan-NETs, Intrahepatic Arterial, Intravenous Infusion, Gastroenteropancreatic (GEP),, Bronchial or Unknown Primary Well Differentiated Neuroendocrine Tumors
Brief summary
This study will look at whether it is practical and safe to give Lutathera directly into an artery of the liver (hepatic intraarterial infusion). The researchers will compare the effects of hepatic intraarterial infusion in the liver with the effects of the standard approach (intravenous infusion in the arm). The researchers will also determine whether Lutathera is effective against participants' cancer.
Interventions
DRUG177Lu-DOTATATE
The treatment regimen will consist of four administrations of 177Lu-DOTATATE-two intra-arterial followed by two intravenous, two months apart (+/- 2 weeks), with renal protective amino acid solution co-administration. The activity per cycle will be fixed for each patient: patients will receive two intra-arterial cycles of 7.4 GBq, unless toxicity occurs requiring dose modifications.
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is an early-phase trial in which a total of 10 patients with progressive, inoperable, liver-dominant, metastatic GEP, bronchial or unknown primary NETs will be enrolled in this combined intraarterial/intravenous therapeutic approach with 177Lu-DOTATATE.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects affected by histologically proven, somatostatin-receptor positive, progressive, nonresectable, liver-dominant metastatic GEP, bronchial or unknown primary tumors, G1, G2 and G3, according to the new WHO classification of 2017. 1. Ability to understand and willingness to sign a written informed consent document 2. Aged 18 years or older 3. Histologically proven or cytologically confirmed, non-resectable,GEP, bronchial or unknown primary NETs with liver-dominant disease with or without prior treatment with embolization 4. Measurable disease as defined by RECIST 1.1 with at least one dimension ≥ 1.0 cm 5. GEP or unknown primary NET of grade 1, 2 and 3 according to WHO 2017, typical or atypical lung carcinoid according to the Travis classification of 2004 6. Progression of disease defined by one of the following occurring within 6 months of study entry: 1. At least a 20% increase in radiologically or clinically measurable disease; 2. Appearance of any new lesion; 3. Symptomatic disease (including worsening hormonal symptoms or symptoms related to tumor burden); 7. Overexpression of somatostatin receptors of the target lesions at 68Ga-DOTATATE PET/CT with SUV of lesions greater than normal liver at least in 1 metastasis. 8. ECOG performance status 0 or 1 (Karnofsky ≥ 70%). 9. Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. 10. Previous local therapy (e.g., chemoembolization or bland embolization) is allowed if completed \>6 weeks prior to study entry. For such patients, there must be either progression of measurable disease documented within the treatment field, or measurable progressive disease outside the treatment field prior to study entry. 11. Previous oral chemotherapy, biotherapy (such as Interferons or Everolimus) and/or investigational agents are allowed if completed \>4 weeks prior to study entry For patients who received systemic therapy prior to study entry, there must be documented progression of measurable disease since receiving systemic therapy prior to study entry. 12. Patients must not be candidate for potentially curative surgery. Prior surgery is allowed no less than 6 weeks prior to study entry. Note: Patients who have disease that is amendable to resection but who are not a surgical candidate for other medical reasons would be permitted.
Exclusion criteria
1. Women who are pregnant or breastfeeding 2. History of allergic reactions attributed to compounds of similar chemical or biologic composition to 177Lu-DOTATATE as assessed from medical records. 3. Life expectancy \< 6 months as assessed by the treating physician. 4. Over 80% liver involvement by tumor per the judgement of the radiologist 5. Poorly differentiated neuroendocrine neoplasms (Neuroendocrine Carcinoma), small and large cell type; Mixed Neuroendocrine-Nonneuroendocrine Neoplasm (MiNEN). 6. Presence of somatostatin receptor negative lesions. 7. Prior treatment with other radiolabeled somatostatin analogs. 8. Prior systemic chemotherapy, except oral chemotherapy with capecitabine + temozolomide 9. Contraindication to angiography/embolization including: 1. Patients cannot receive contrast 2. Severe allergic reaction to contrast despite premedication. Patients in who IV contrast is contraindicated are recommended to have MRI abdomen and noncontrast chest CT scan. 3. Poor renal function not on dialysis 4. Other, based on judgment of the investigator 10. Main portal vein tumor thrombus. 11. Deteriorated renal function: 1. Serum creatinine \>1.7 mg/dL OR 2. EGFR \<30 ml/min 12. Deteriorated bone marrow function: 1. Hb \<8.0 g/dL; 2. WBC \<3000/mm3; 3. ANC\<1500/mm3; 4. Platelets \<75.000/mm3 13. Deteriorated liver function: 1. INR \> 2.0 for patients that are not on Coumadin or Xarelto 2. PTT \> 2x ULN 3. Total bilirubin \>3 mg/dl 4. Serum albumin \<3.0 g/dL unless prothrombin time is within the normal range. 14. Clinically relevant toxicities from prior therapies that have not resolved to grade 1 or grade 0 15. Previous liver radioembolization with 90Y-microspheres. 16. Known brain metastases and/or carcinomatous meningitis, unless these metastases have been treated and stabilized. 17. Uncontrolled diabetes mellitus 18. Inability to interrupt short-acting Octreotide for 24 h before and 24 h after the administration of 177Lu-DOTATATE; inability to have an interval between Octreotide LAR and 177Lu-DOTATATE of ≥4 weeks 19. Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 20. Prior external beam radiation therapy involving \>25% of the bone marrow. 21. Unmanageable urinary incontinence rendering the administration of 177Lu-DOTATATE unsafe 22. Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and with no evidence of recurrence.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| number of patients who successfully complete 2 IA injections | 2 years | Feasibility will be defined as at least 7 or more patients out of 10 patients who successfully complete 2 IA injections. |
| Objective response | 1 year | classified according to RECIST 1.1 criteria |
Countries
United States
Outcome results
None listed